PLIN2 and neoplasm: NNMT, PLOD2, HAPLN3, PLIN2, and SLC16A3 showed medium to strong tumor-specific staining in more than 90% renal cancer samples, indicating higher general applicability of these biomarkers (Fig. 4k).